Interestingly, STORM Therapeutics announced phase 1 clinical trials of its METTL3-targeting drug STC-15 for refractory acute myeloid leukemia (AML) in 2020, after promising results in mice [91], meaning that STC-15 is the first METTL3 inhibitor to enter clinical trials and the initial results are expected to be released shortly (ClinicalTrials.gov: NCT05584111). This evidence concerns the gene METTL3 and acute myeloid leukemia.